Hemophilia Treatment Market to Reach $26.9 Billion Globally by 2031 at a CAGR of 7.5%: Allied Market Research

Rising prevalence of hemophilia, technological advancements in hemophilia treatment, and government initiatives to support hemophilia management are driving the growth of the global hemophilia treatment market.

PORTLAND, Oregon., July 6, 2022 /PRNewswire/ — Allied Market Research recently released a report titled, Hemophilia Treatment Market By Type (Hemophilia A, Hemophilia B), By Drug Therapy (Recombinant Clotting Factor Concentrate Therapy, Plasma-Derived Clotting Factor Concentrate Therapy, Non-Factor Replacement Therapy, Others): Global Opportunity Analysis and Market Forecast industry, 2021-2031. » According to the report, the global hemophilia treatment industry generated $12.8 billion in 2021, and should reach $26.9 billion by 2031, with a CAGR of 7.5% from 2022 to 2031.

Allied_Market_Research_Logo

Download a sample PDF at: https://www.alliedmarketresearch.com/request-sample/301

Drivers, constraints and opportunities

Rising prevalence of hemophilia, technological advancements in hemophilia treatment, and government initiatives to support hemophilia management are driving the growth of the global hemophilia treatment market. However, the high cost of hemophilia treatments and adverse reactions associated with plasma-derived products are restraining the market growth. On the other hand, the increase in R&D activities concerning therapeutic therapies, the increase in the use of prophylactic treatments and the increase in the rate of diagnosis create new opportunities for the market growth in the coming years.

Covid-19 scenario

  • Due to social distancing measures, the possibility of cross-contamination and the postponement of non-elective surgeries, the number of hemophilia treatments has dropped significantly during the Covid-19 pandemic. This has had a negative impact on the global haemophilia treatment market.

  • Manufacturers have also suffered huge losses during the pandemic, due to reduced demand for hemophilia drugs for treatment. However, the market is expected to recover after the pandemic.

The hemophilia A segment will maintain its leading status throughout the forecast period

By type, the hemophilia A segment accounted for the highest market share in 2021, contributing more than four-fifths of the global hemophilia treatment market, and is expected to maintain its leading status throughout the forecast period. Additionally, this segment is expected to show the fastest CAGR of 7.6% from 2022 to 2031. This is attributed to increasing incidence of hemophilia A, increasing use of factor VIII and product approvals by regulatory authorities. The report also analyzes the hemophilia B segment.

Specific requirement on COVID-19? Ask our industry expert: https://www.alliedmarketresearch.com/request-for-customization/301?reqfor=covid

Recombinant Clotting Factor Focuses Therapeutic Segment to Maintain Leadership Status by 2031

Based on drug therapy, the recombinant clotting factor concentrate therapy segment held the highest share in 2021, accounting for more than two-fifths of the global hemophilia treatment market, and is expected to maintain its leading status by 2031. This is expected to increase in the number of recombinant technology products available for treatment. However, the non-factor replacement therapy segment is expected to experience the Highest CAGR of 8.6% from 2022 to 2031, due to the increase in the target population and the increase in R&D activities for therapeutic therapies.

Europe maintain its leading position by 2031

Based on the region, Europe contributed the highest market share in terms of revenue in 2021, accounting for more than two-fifths of the global hemophilia treatment market, and is expected to maintain its leading position by 2031. This is attributed to institutions of well-established healthcare, technology advances and increasing demand for early diagnosis of hemophilia. However, Asia Pacific is estimated to witness the highest CAGR of 8.3% during the forecast period. This is due to the increase in the incidence of the population suffering from hemophilia and the increase in healthcare expenditure.

Main market players

  • Bayer AG

  • CSL Ltd. (CSL Behring)

  • F. Hoffmann-La Roche SA

  • Grifols, SA

  • Medexus Pharmaceuticals Inc.

  • Novo Nordisk A/S

  • Octapharma S.A.

  • Pfizer Inc.

  • Swedish orphan Biovitrum AB

  • Takeda Pharmaceuticals Company Ltd.

Avenue Basic Plan | Access to the library | 1 year subscription |

Sign up for the Avenue subscription to access over 12,000 company profiles and over 2,000 niche market research reports on $699 per month, per seat. For one year, the customer must purchase a minimum 2-seat plan.

14-day free trial request: https://www.alliedmarketresearch.com/avenue/trial/starter

“We have also published some syndicated market studies in the same field that you may be interested in. Below is the title of the report for your referenceconsidering the impact of Covid-19 on this market which will help you to assess the aftereffects of the pandemic on the short and long term growth trends of this market.”

Reports on trends in the healthcare industry (book now with 10% discount):

Fertility Supplements Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Infection Control Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Clinical Trial Imaging Services Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Neurodiagnostics Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Sperm Bank Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Contraceptive Drugs Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

E-Health Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Spirometer Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Digital Health Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

Healthcare CRM Market – Global Opportunity Analysis and Industry Forecast, 2020-2028

About Us

Allied Market Research (AMR) is a full-service market research and business advisory division of Allied Analytics LLP based in Portland, OR. Allied Market Research provides global corporations as well as small and medium enterprises with unrivaled quality of “market research reports” and “Business Intelligence solutions“. AMR has a focused vision to provide business insights and advice to help its clients make strategic business decisions and achieve sustainable growth in their respective market area.

Pawan KumarCEO of Allied Market Research, directs the organization towards the provision of high quality data and information. We maintain professional relationships with various companies which helps us to extract market data which helps us to generate accurate research data tables and confirm the utmost accuracy of our market predictions. All data presented in the reports we publish are drawn from primary interviews with senior managers of large companies in the relevant field. Our secondary data sourcing methodology includes extensive online and offline research and discussions with knowledgeable industry professionals and analysts.


Contact:
David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
UNITED STATES/Canada (Free): +1-800-792-5285, +1-503-894-6022
UK: +44-845-528-1300
hong kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1(855)550-5975
help@alliedmarketresearch.com
The Web: https://www.alliedmarketresearch.com/reports-store/life-sciences
Follow us on LinkedIn: https://www.linkedin.com/showcase/life-sciences-industry-research/

Logo: https://mma.prnewswire.com/media/636519/Allied_Market_Research_Logo.jpg

Quote

Quote

Show original content:https://www.prnewswire.com/news-releases/hemophilia-treatment-market-to-reach-26-9-bn-globally-by-2031-at-7-5-cagr-allied-market-research- 301580557.html

SOURCE Allied Market Research


Source link

Sandy A. Greer